Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “buy” rating on the stock.

Trinity Biotech Trading Up 2.7 %

Trinity Biotech stock opened at $0.77 on Friday. The firm has a market capitalization of $29.41 million, a P/E ratio of -0.82 and a beta of 1.41. The stock has a fifty day moving average price of $0.96 and a 200 day moving average price of $0.98. Trinity Biotech has a 52 week low of $0.63 and a 52 week high of $1.44.

Get Trinity Biotech alerts:

Trinity Biotech (NASDAQ:TRIB – Get Free Report) last released its earnings results on Thursday, July 6th. The company reported ($0.16) EPS for the quarter. The business had revenue of $14.83 million during the quarter. Trinity Biotech had a negative net margin of 48.76% and a negative return on equity of 870.11%. As a group, equities analysts predict that Trinity Biotech will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Trinity Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. Atria Wealth Solutions Inc. purchased a new position in Trinity Biotech in the first quarter valued at about $27,000. Virtu Financial LLC purchased a new position in Trinity Biotech in the first quarter valued at about $40,000. Cambridge Investment Research Advisors Inc. purchased a new position in Trinity Biotech in the second quarter valued at about $106,000. Whitefort Capital Management LP boosted its holdings in Trinity Biotech by 1,067.8% in the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares during the last quarter. Finally, Hunter Associates Investment Management LLC boosted its holdings in Trinity Biotech by 1.5% in the fourth quarter. Hunter Associates Investment Management LLC now owns 1,823,633 shares of the company’s stock valued at $1,809,000 after purchasing an additional 26,443 shares during the last quarter. Hedge funds and other institutional investors own 16.59% of the company’s stock.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

• Five stocks we like better than Trinity Biotech
• There Are Different Types of Stock To Invest In
• Investing in Coffee: 3 Great Strategies to Consider
• How to Most Effectively Use the MarketBeat Earnings Screener
• 5 Best Stocks to Buy in a Bear Market
• Best Aerospace Stocks Investing
• 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.